{"id":62641,"date":"2026-04-08T21:11:20","date_gmt":"2026-04-08T13:11:20","guid":{"rendered":"https:\/\/flcube.com\/?p=62641"},"modified":"2026-04-08T21:11:21","modified_gmt":"2026-04-08T13:11:21","slug":"insilico-medicine-advances-ai-discovered-nr3c1-antagonist-ism6200-into-clinical-development-for-ovarian-cancer-and-cortisol-excess-disorders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62641","title":{"rendered":"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders"},"content":{"rendered":"\n<p><strong>Insilico Medicine (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>)<\/strong>, a China-based artificial intelligence drug discovery platform, announced the selection of <strong>ISM6200<\/strong> for clinical development, targeting <strong>ovarian cancer<\/strong>, <strong>Cushing&#8217;s syndrome<\/strong>, and other <strong>cortisol-excess-related diseases<\/strong> including hypercortisolism-associated obesity. The candidate was discovered and optimized using Insilico&#8217;s proprietary <strong>Chemistry42 generative chemistry engine<\/strong> within its <strong>Pharma.AI platform<\/strong>, demonstrating superior preclinical efficacy and low drug-drug interaction risk.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-candidate-profile\">Drug Candidate Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Insilico Medicine (HKG: 3696)<\/td><\/tr><tr><td><strong>Candidate<\/strong><\/td><td>ISM6200<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Small-molecule NR3C1 (glucocorticoid receptor) antagonist<\/td><\/tr><tr><td><strong>Discovery Platform<\/strong><\/td><td>Chemistry42 generative chemistry engine (Pharma.AI platform)<\/td><\/tr><tr><td><strong>Primary Indications<\/strong><\/td><td>Ovarian cancer, Cushing&#8217;s syndrome, cortisol-excess disorders<\/td><\/tr><tr><td><strong>Secondary Indications<\/strong><\/td><td>Hypercortisolism-associated obesity<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical completion, advancing to clinical development<\/td><\/tr><tr><td><strong>Key Differentiator<\/strong><\/td><td>AI-discovered with optimized properties and low DDI risk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ai-driven-discovery-amp-optimization\">AI-Driven Discovery &amp; Optimization<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chemistry42-platform-innovation\">Chemistry42 Platform Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Generative Chemistry<\/strong>: AI-powered molecular generation and optimization capabilities<\/li>\n\n\n\n<li><strong>Target Focus<\/strong>: NR3C1 (nuclear receptor subfamily 3 group C member 1) \u2013 glucocorticoid receptor<\/li>\n\n\n\n<li><strong>Property Optimization<\/strong>: Simultaneous optimization of potency, selectivity, and drug-like properties<\/li>\n\n\n\n<li><strong>Development Timeline<\/strong>: Accelerated discovery-to-candidate timeline through AI-driven design cycles<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-core-module-integration\">Core Module Integration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Identification<\/strong>: AI-powered target validation for cortisol-excess pathways<\/li>\n\n\n\n<li><strong>Molecular Design<\/strong>: Generative models creating novel chemical matter with desired properties<\/li>\n\n\n\n<li><strong>ADMET Prediction<\/strong>: Integrated pharmacokinetic and safety property prediction<\/li>\n\n\n\n<li><strong>Synthetic Feasibility<\/strong>: Real-time assessment of compound synthesizability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-efficacy-data\">Preclinical Efficacy Data<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-in-vivo-superiority\">In Vivo Superiority<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Animal Models<\/strong>: Demonstrated superior efficacy across multiple preclinical animal models<\/li>\n\n\n\n<li><strong>Dose Response<\/strong>: Clear dose-dependent activity confirming target engagement<\/li>\n\n\n\n<li><strong>Therapeutic Window<\/strong>: Favorable safety margin in toxicology studies<\/li>\n\n\n\n<li><strong>Pharmacokinetics<\/strong>: Optimized exposure profiles supporting once-daily or less frequent dosing<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ovarian-cancer-combination-therapy\">Ovarian Cancer Combination Therapy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Model System<\/strong>: CDX (cell-derived xenograft) tumor cell transplantation mouse models<\/li>\n\n\n\n<li><strong>Combination Partner<\/strong>: Paclitaxel (standard-of-care chemotherapy)<\/li>\n\n\n\n<li><strong>Synergistic Effect<\/strong>: Significant dose-dependent increase in antitumor efficacy versus paclitaxel alone<\/li>\n\n\n\n<li><strong>Mechanistic Rationale<\/strong>: NR3C1 antagonism potentially overcomes glucocorticoid-mediated chemoresistance<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-rationale-amp-market-opportunity\">Therapeutic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cortisol-excess-disease-landscape\">Cortisol-Excess Disease Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cushing&#8217;s Syndrome<\/strong>: Rare endocrine disorder with limited treatment options and significant morbidity<\/li>\n\n\n\n<li><strong>Ovarian Cancer<\/strong>: High unmet need in recurrent\/refractory disease with poor prognosis<\/li>\n\n\n\n<li><strong>Hypercortisolism-Associated Obesity<\/strong>: Emerging indication with potential for significant market impact<\/li>\n\n\n\n<li><strong>NR3C1 Target Validation<\/strong>: Glucocorticoid receptor antagonism addresses root cause of cortisol excess effects<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Origin<\/strong>: First-in-class potential as AI-discovered NR3C1 antagonist<\/li>\n\n\n\n<li><strong>Low DDI Risk<\/strong>: Optimized for minimal drug-drug interactions, critical for combination therapies<\/li>\n\n\n\n<li><strong>Oral Bioavailability<\/strong>: Small-molecule format enabling convenient oral administration<\/li>\n\n\n\n<li><strong>Multi-Indication Strategy<\/strong>: Single molecule addressing multiple cortisol-excess related conditions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-development-pathway\">Strategic Implications &amp; Development Pathway<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-insilico-s-ai-platform-validation\">Insilico&#8217;s AI Platform Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Translation<\/strong>: Represents successful translation of AI-discovered molecules to clinical development<\/li>\n\n\n\n<li><strong>Platform Credibility<\/strong>: Validates Chemistry42 and Pharma.AI platform capabilities for complex targets<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Demonstrates ability to generate diverse therapeutic candidates beyond initial focus areas<\/li>\n\n\n\n<li><strong>Investor Confidence<\/strong>: Strengthens position as leader in AI-driven drug discovery<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-strategy\">Development Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Initial Indication<\/strong>: Likely prioritization of ovarian cancer based on strong combination data<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Potential for orphan drug designation in Cushing&#8217;s syndrome<\/li>\n\n\n\n<li><strong>Clinical Trial Design<\/strong>: Combination studies with standard-of-care agents in oncology indications<\/li>\n\n\n\n<li><strong>Timeline Expectations<\/strong>: IND filing expected within 12-18 months based on preclinical package completion<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-commercial-outlook\">Market Context &amp; Commercial Outlook<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ai-drug-discovery-evolution\">AI Drug Discovery Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Industry Maturation<\/strong>: Transition from AI platform validation to clinical candidate advancement<\/li>\n\n\n\n<li><strong>Investment Trends<\/strong>: Increasing capital allocation to AI-discovered clinical programs<\/li>\n\n\n\n<li><strong>Partnership Opportunities<\/strong>: Potential for pharma partnerships to fund later-stage development<\/li>\n\n\n\n<li><strong>Valuation Impact<\/strong>: Clinical candidates typically command significant premium over preclinical assets<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-area-dynamics\">Therapeutic Area Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ovarian Cancer Market<\/strong>: Large addressable population with high unmet need for effective therapies<\/li>\n\n\n\n<li><strong>Endocrine Disorders<\/strong>: Specialized markets with premium pricing and lower competitive intensity<\/li>\n\n\n\n<li><strong>Obesity Adjacent<\/strong>: Hypercortisolism-associated obesity represents gateway to broader metabolic indications<\/li>\n\n\n\n<li><strong>Global Reach<\/strong>: Indications with worldwide prevalence enabling international commercial strategy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-risk-considerations-amp-challenges\">Risk Considerations &amp; Challenges<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Translation Risk<\/strong>: Historical challenges in translating preclinical efficacy to human patients<\/li>\n\n\n\n<li><strong>Target Safety<\/strong>: NR3C1 antagonism requires careful monitoring for adrenal insufficiency and related effects<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Potential competition from other glucocorticoid receptor modulators in development<\/li>\n\n\n\n<li><strong>AI Platform Dependence<\/strong>: Continued reliance on proprietary AI platforms for future pipeline success<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, AI platform performance, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[4514,164],"class_list":["post-62641","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of ISM6200 for clinical development, targeting ovarian cancer, Cushing&#039;s syndrome, and other cortisol-excess-related diseases including hypercortisolism-associated obesity. The candidate was discovered and optimized using Insilico&#039;s proprietary Chemistry42 generative chemistry engine within its Pharma.AI platform, demonstrating superior preclinical efficacy and low drug-drug interaction risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62641\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of ISM6200 for clinical development, targeting ovarian cancer, Cushing&#039;s syndrome, and other cortisol-excess-related diseases including hypercortisolism-associated obesity. The candidate was discovered and optimized using Insilico&#039;s proprietary Chemistry42 generative chemistry engine within its Pharma.AI platform, demonstrating superior preclinical efficacy and low drug-drug interaction risk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62641\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T13:11:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T13:11:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62641#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62641\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders\",\"datePublished\":\"2026-04-08T13:11:20+00:00\",\"dateModified\":\"2026-04-08T13:11:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62641\"},\"wordCount\":687,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62641#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62641\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62641\",\"name\":\"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T13:11:20+00:00\",\"dateModified\":\"2026-04-08T13:11:21+00:00\",\"description\":\"Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of ISM6200 for clinical development, targeting ovarian cancer, Cushing's syndrome, and other cortisol-excess-related diseases including hypercortisolism-associated obesity. The candidate was discovered and optimized using Insilico's proprietary Chemistry42 generative chemistry engine within its Pharma.AI platform, demonstrating superior preclinical efficacy and low drug-drug interaction risk.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62641#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62641\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62641#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of ISM6200 for clinical development, targeting ovarian cancer, Cushing's syndrome, and other cortisol-excess-related diseases including hypercortisolism-associated obesity. The candidate was discovered and optimized using Insilico's proprietary Chemistry42 generative chemistry engine within its Pharma.AI platform, demonstrating superior preclinical efficacy and low drug-drug interaction risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62641","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders","og_description":"Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of ISM6200 for clinical development, targeting ovarian cancer, Cushing's syndrome, and other cortisol-excess-related diseases including hypercortisolism-associated obesity. The candidate was discovered and optimized using Insilico's proprietary Chemistry42 generative chemistry engine within its Pharma.AI platform, demonstrating superior preclinical efficacy and low drug-drug interaction risk.","og_url":"https:\/\/flcube.com\/?p=62641","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T13:11:20+00:00","article_modified_time":"2026-04-08T13:11:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62641#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62641"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders","datePublished":"2026-04-08T13:11:20+00:00","dateModified":"2026-04-08T13:11:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62641"},"wordCount":687,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 3696","Insilico Medicine"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62641#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62641","url":"https:\/\/flcube.com\/?p=62641","name":"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T13:11:20+00:00","dateModified":"2026-04-08T13:11:21+00:00","description":"Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of ISM6200 for clinical development, targeting ovarian cancer, Cushing's syndrome, and other cortisol-excess-related diseases including hypercortisolism-associated obesity. The candidate was discovered and optimized using Insilico's proprietary Chemistry42 generative chemistry engine within its Pharma.AI platform, demonstrating superior preclinical efficacy and low drug-drug interaction risk.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62641#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62641"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62641#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62641"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62641\/revisions"}],"predecessor-version":[{"id":62643,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62641\/revisions\/62643"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}